

Study name	N	Population (treatment naïve or experienced)	Duration of reported ADEs (weeks)	Drug studied	Comparator	Dose (mg/day)	Dose comparat or (mg/day)	Sex (male %)	Jadad score
Cahn, et al., 2014*	719	Experienced	48	dolutegravir	raltegravir	50	800	68	5
Dooley, et al., 2019*	113	Naïve	52	dolutegravir	efavirenz	50	600	59	3
Llibre et al., 2018*	102 4	Experienced	52	dolutegravir + rilpivirine	current ART regimen	dolutegra vir 50 mg + rilpivirin e 25 mg	varies	77	3
Molina, et al., 2015*	485	Naïve	96	dolutegravir	darunavir + ritonavir	50	darunavir 800 mg + ritonavir 100 mg	85	3
Molina, et al., 2018*	563	Experienced	48	dolutegravir	bictegravir	50	50	89	5
NCT005437 25 (THRIVE)	678	Naïve	164	rilpivirine	efavirenz	25	600	73	5

NCT005404 49 (ECHO)	690	Naïve	160	rilpivirine	efavirenz	25	600	79	5
NCT012630 15 (SINGLE)	833	Naïve	144	dolutegravir	efavirenz	50	600	84	5
NCT017090 84 (SALIF)	424	Experienced	48	rilpivirine	efavirenz	25	600	36	2
NCT022272 38	624	Experienced	52	dolutegravir	lopinavir + ritonavir	50	lopinavir 800 mg + ritonavir 200 mg	65	3
NCT026079 30	629	Naïve	144	dolutegravir	bictegravir	50	50	90	5
NCT026079 56	645	Naïve	144	dolutegravir	bictegravir	50	50	88	5
NCT031103 80	565	Experienced	48	dolutegravir	bictegravir	50	50	86	5
Orrell, et al., 2017	495	Naïve	48	dolutegravir	atazanavir + ritonavir	50	atazanavir 300 mg + ritonavir 100 mg	0	3
Raffi, et al., 2013*	822	Naïve	96	dolutegravir	raltegravir	50	800	86	5
Sax, et al., 2017*	98	Naïve	48	dolutegravir	bictegravir	50	75	96	5

Stellbrink, et al., 2013*	101	Naïve	96	dolutegravir	efavirenz	50	600	86	2
Trottier, et al., 2017*	553	Experienced	24	dolutegravir	current ART regimen	50	varies	86	3
Vera, et al., 2019*	41	Experienced	24	rilpivirine	efavirenz	25	600	92	1
Wilkins, et al., 2015*	786	Naïve	96	rilpivirine	efavirenz	25	600	93	3
* clinical.gov site provided additional information not found in the study									

Table S1: Study characteristics